Trodelvy® is now FDA-approved as a first-line treatment option for patients with metastatic triple-negative breast cancer, expanding its role in frontline care.
Gilead Sciences has secured a major new U.S. regulatory milestone for Trodelvy (sacituzumab govitecan-hziy), with the U.S. Food and Drug Administration approving the Trop-2-directed antibody-drug conjugate for first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). The decision significantly broadens Trodelvy’s role in breast cancer and positions the therapy as a new frontline option for one of the most aggressive and difficult-to-treat forms of the disease. (Gilead)
Under the new approval, Trodelvy can now be used in two distinct first-line settings. It is approved as a single agent for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. It is also approved in combination with pembrolizumab—marketed by Merck as Keytruda and Keytruda Qlex—for patients whose tumors are PD-L1 positive, defined as a combined positive score (CPS) of 10 or greater using an FDA-authorized test. Together, the two indications allow Gilead to position Trodelvy across the first-line metastatic TNBC population regardless of PD-L1 status, either alone or in an immunotherapy-based regimen. (Gilead)
The approval is based on results from the Phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 studies, which showed that Trodelvy-based regimens significantly improved progression-free survival compared with chemotherapy-containing standards of care. For Gilead, the label expansion represents more than a routine regulatory win. It moves Trodelvy from a therapy already established in later-line metastatic breast cancer into the frontline treatment setting, where physicians make the most consequential decisions for patients with metastatic TNBC and where the opportunity to influence the course of disease may be greatest. (Gilead)
A New First-Line Option in One of the Most Aggressive Breast Cancer Subtypes
Triple-negative breast cancer accounts for a smaller share of breast cancer diagnoses than hormone receptor-positive disease, but it remains one of the most feared subtypes because of its aggressive clinical behavior, higher risk of recurrence, and historically limited treatment options. TNBC lacks expression of estrogen receptor, progesterone receptor, and HER2, meaning it does not respond to endocrine therapy or HER2-targeted medicines that have transformed outcomes in other breast cancer settings. As a result, chemotherapy has long remained a cornerstone of treatment, particularly in the metastatic setting. (U.S. Food and Drug Administration)
The stakes are especially high in metastatic TNBC, where the disease has spread beyond the breast and regional lymph nodes and becomes largely incurable. In this setting, clinicians aim to prolong survival, control symptoms, preserve quality of life, and delay progression for as long as possible. But treatment sequencing is complicated by the reality that many patients do not reach multiple subsequent lines of therapy. That means the first-line choice often carries disproportionate weight, making improvements in the frontline setting particularly important.
That context helps explain why Gilead and outside clinicians have described the approval as a potentially practice-changing event. Sara Tolaney of Dana-Farber Cancer Institute, one of the principal investigators of the ASCENT studies, emphasized that many patients with metastatic TNBC may not have the chance to receive later therapies, making the initial treatment decision especially pivotal. The approval, she said, gives clinicians a new first-line option across PD-L1-defined patient groups and could reshape how metastatic TNBC is treated from the start. (Gilead)
Trodelvy Moves Into the Frontline With Data From Two Pivotal Trials
The FDA’s decision rests on two Phase 3 studies designed to address different segments of the first-line metastatic TNBC population.
The first, ASCENT-03, evaluated Trodelvy as monotherapy in patients with PD-L1-ineligible disease—in other words, patients who were not candidates for PD-1 or PD-L1 inhibitor-based therapy. In this trial, Trodelvy reduced the risk of disease progression or death by 38% compared with chemotherapy. The regimen also produced more durable responses, with a median duration of response of 12.2 months, compared with 7.2 months for chemotherapy. (Gilead)
The second, ASCENT-04/KEYNOTE-D19, focused on patients whose tumors expressed PD-L1 and therefore could be treated with an immunotherapy-based regimen. In this study, Trodelvy plus pembrolizumab reduced the risk of progression or death by 35% compared with pembrolizumab plus chemotherapy. Here again, the durability of benefit stood out: median duration of response reached 16.5 months with the Trodelvy combination, versus 9.2 months in the chemotherapy-containing comparator arm, based on blinded independent central review. (Gilead)
Together, the trials create a broad clinical package that supports Trodelvy across first-line metastatic TNBC rather than only in a narrow molecularly defined segment. For Gilead, that is strategically important because it enables the company to frame Trodelvy as a “backbone” therapy in frontline mTNBC—either replacing chemotherapy in certain patients or serving as a key partner to immunotherapy in PD-L1-positive disease.
Building on Trodelvy’s Established Role in Later-Line Breast Cancer
Trodelvy is not new to metastatic breast cancer, but this approval significantly elevates its position in the treatment landscape. The drug was already approved in second-line or later metastatic TNBC and in certain patients with pre-treated HR-positive, HER2-negative metastatic breast cancer. Those approvals helped establish Trodelvy as one of the most commercially and clinically important antibody-drug conjugates in breast cancer, particularly after the therapy demonstrated overall survival benefit in pretreated metastatic TNBC. (Gilead)
With the new first-line indication, Trodelvy moves much earlier in the treatment pathway. That matters both clinically and commercially. From a clinical perspective, earlier use may allow more patients to benefit from the therapy before their disease becomes more resistant or their performance status declines. From a business standpoint, first-line use generally opens a much larger opportunity than later-line treatment because more patients are eligible and therapy durations may be longer if the drug works well.
Gilead says healthcare professionals now have substantial experience with Trodelvy, with more than 75,000 breast cancer patients treated globally across more than 60 countries over the past six years. The company also notes that Trodelvy remains the only Trop-2-directed ADC to demonstrate meaningful overall survival benefit in both later-line metastatic TNBC and pretreated HR+/HER2-negative metastatic breast cancer, and the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer. (Gilead)
Those claims are central to how Gilead is trying to distinguish Trodelvy in an increasingly crowded ADC market. The antibody-drug conjugate space has become one of the hottest areas in oncology, with multiple companies advancing Trop-2- and HER2-directed agents into breast cancer and other solid tumors. By moving Trodelvy into the frontline TNBC setting with positive Phase 3 data across PD-L1 groups, Gilead is trying to reinforce the drug’s leadership position just as competition intensifies.
NCCN Support Strengthens Trodelvy’s Position
The regulatory approval is also reinforced by treatment guideline support. Based on the ASCENT-03 and ASCENT-04 data, the National Comprehensive Cancer Network (NCCN) recommends Trodelvy with or without pembrolizumab as a Category 1 preferred first-line option for metastatic TNBC across PD-L1 status in the current NCCN breast cancer guidelines, according to Gilead. Trodelvy also holds a Category 1 recommendation in second-line metastatic TNBC and in pre-treated HR-positive/HER2-negative metastatic breast cancer. (Gilead)
That matters because NCCN recommendations often play a major role in shaping oncologist adoption and payer reimbursement. A frontline approval alone can be significant, but pairing it with Category 1 preferred status gives Trodelvy additional momentum as clinicians update treatment algorithms and insurers evaluate coverage decisions.
A New Option for Patients Long Limited by Chemotherapy
For patients and advocacy groups, the approval represents progress in a disease area where treatment innovation has often lagged behind other breast cancer subtypes. Triple-negative disease disproportionately affects younger women, is more common in Black women, and is associated with poorer outcomes than many other forms of breast cancer. In the metastatic setting, chemotherapy has long remained the default first-line approach for many patients, even though responses are often short-lived and side effects can be substantial.
Ricki Fairley, CEO and co-founder of TOUCH, The Black Breast Cancer Alliance, said the approval offers a new source of hope for a patient community that has historically had few choices. Because so many patients with metastatic TNBC may never receive second- or third-line therapy, she noted, having access to a promising frontline option such as Trodelvy—with or without pembrolizumab—can make a meaningful difference. The approval is particularly significant, she argued, because the field has sought alternatives to chemotherapy-containing first-line regimens for more than two decades. (Gilead)
That patient perspective underscores a broader trend in oncology: the shift away from traditional chemotherapy alone and toward more targeted or biomarker-guided therapies. Trodelvy is still an ADC that delivers a cytotoxic payload, but it does so through a targeted antibody approach aimed at Trop-2, a cell surface antigen highly expressed in many epithelial cancers, including TNBC. That design allows the drug to deliver chemotherapy more selectively to tumor cells while also creating a bystander effect in the tumor microenvironment. (Gilead)
Safety Profile Remains Familiar, but Monitoring Is Critical
As with its prior indications, Trodelvy carries a significant safety profile that clinicians must manage carefully. The prescribing information includes a boxed warning for neutropenia and diarrhea, both of which can be severe, life-threatening, or even fatal in some cases. The FDA and Gilead advise regular blood count monitoring during treatment, with growth factor support recommended for patients at increased risk of febrile neutropenia. Patients experiencing severe diarrhea require prompt evaluation, supportive care, and treatment interruption or dose modification when appropriate. (Gilead)
In the ASCENT-03 monotherapy study, the most common adverse reactions occurring in at least 25% of patients included nausea, diarrhea, alopecia, fatigue, constipation, and vomiting. Serious adverse reactions seen in more than 2% of patients included diarrhea, febrile neutropenia, neutropenia, and pneumonia. Fatal adverse reactions occurred in a small proportion of patients and included sepsis, acute respiratory failure, neutropenic colitis, pneumonia, and septic shock. (Gilead)
In the ASCENT-04 combination study with pembrolizumab, the most common adverse reactions included diarrhea, nausea, fatigue, alopecia, constipation, rash, vomiting, abdominal pain, and headache. Serious adverse reactions included febrile neutropenia, neutropenia, diarrhea, fatigue, and pneumonia, with a small number of fatal events also reported. As in ASCENT-03, decreased neutrophils and leukocytes were among the most common Grade 3-4 laboratory abnormalities. (Gilead)
These safety considerations mean Trodelvy is not a simple “lighter” alternative to chemotherapy; rather, it is a more targeted therapy with its own distinct and sometimes substantial toxicities. Still, oncologists are increasingly comfortable managing these risks, given the drug’s existing use in later-line breast cancer and the growing experience with ADCs across oncology.
A Strategic Win for Gilead’s Oncology Ambitions
For Gilead, the approval is an important validation of its oncology strategy and of Trodelvy as one of the company’s most important cancer assets. Since acquiring Immunomedics and bringing Trodelvy into its portfolio, Gilead has invested heavily in expanding the drug across breast cancer and other tumor types. The first-line TNBC approval is one of the clearest signs yet that the company is succeeding in moving the asset into earlier lines of treatment, where it can have greater clinical and commercial impact.
Dietmar Berger, Gilead’s chief medical officer, said the approval establishes a new standard of care in the most aggressive form of breast cancer and gives patients a new backbone therapy option after more than 20 years of limited frontline choices in metastatic TNBC. The company is also continuing to evaluate Trodelvy in multiple ongoing Phase 3 trials across other tumor types and earlier treatment settings, including potentially curative breast cancer settings as well as lung and gynecologic cancers. (Gilead)
Redefining the Frontline TNBC Landscape
The FDA approval of Trodelvy in first-line metastatic triple-negative breast cancer represents a meaningful shift in the treatment landscape. It gives oncologists a new targeted therapy option across both PD-L1-positive and PD-L1-ineligible disease, supported by Phase 3 data showing clear improvements in progression-free survival and response durability compared with chemotherapy-based standards. For patients facing a diagnosis of metastatic TNBC, that is significant, because the first treatment they receive may be their best opportunity to gain durable control over an aggressive disease.
For Gilead, the decision deepens Trodelvy’s footprint in breast cancer and strengthens its standing in the fast-moving ADC market. For the broader field of oncology, it is another sign that antibody-drug conjugates are moving from later-line rescue therapies into frontline backbone regimens capable of challenging chemotherapy in some of the toughest tumor types. And for patients with metastatic TNBC—a group long underserved by therapeutic innovation—it offers a new frontline option at a point in care where every month without progression matters.
